Ambrose Kristen 4

What Happened

• Kristen Ambrose, Senior Vice President & Chief Accounting Officer at Vertex Pharmaceuticals (VRTX), was granted 1,809 restricted stock units (RSUs) on Feb 17, 2026 (recorded as an acquisition at $0.00). On Feb 17–18, 2026 she disposed a total of 2,793 shares across three transactions — 598 shares withheld/sold to satisfy tax liability at $483.75 ($289,283), 1,557 shares sold on the open market at $489.46 ($762,089), and 638 shares sold on the open market at $473.68 ($302,208). Total proceeds from the reported disposals were about $1.35 million. These actions are primarily sales (routine liquidity/tax actions), not purchases.

Key Details

• Dates and prices:
  • 2026-02-17: Award of 1,809 RSUs @ $0.00 (Acquisition)
  • 2026-02-17: 598 shares disposed for tax withholding @ $483.75 (F) — $289,283
  • 2026-02-17: 1,557 shares sold open market @ $489.46 (S) — $762,089
  • 2026-02-18: 638 shares sold open market @ $473.68 (S) — $302,208
• Total shares disposed: 2,793; total proceeds ≈ $1,353,580.
• Shares owned after transaction: Not specified in the provided filing data.
• Footnotes:
  • F1: The award is RSUs that vest in installments beginning Feb 20, 2027.
  • F2: The open-market sales were made under an approved Rule 10b5-1 trading plan (entered 08/08/2025).
• Filing timeliness: Reporting period 02/17/2026; filing date 02/19/2026 — appears to be filed within the required Form 4 timeframe (not indicated as late).

Context

• The RSU grant is a non-cash award that vests in the future (starting Feb 20, 2027). The 598-share disposal coded F indicates shares were used to cover tax obligations. The other sales were executed under a pre-established 10b5‑1 plan, which typically schedules trades in advance and is considered routine. These dispostions are not a direct bullish signal; purchases would be more indicative of positive insider conviction.